Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark L Heaney

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Cancer Research|October 3, 2008
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugsMark L Heaney, Jeffrey R Gardner, Nicos Karasavvas, et al.
Cancer|July 29, 2009
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropeniaMark L Heaney, Edmond L Toy, Francis Vekeman, et al.
Nucleic Acid Therapeutics|July 16, 2013
A self-assembling short oligonucleotide duplex suitable for pretargetingPrabodhika Mallikaratchy, Jeffery Gardner, Lars Ulrik R Nordstrøm, et al.
Cancer|February 6, 2003
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericinTimothy B Aliff, Peter G Maslak, Joseph G Jurcic, et al.
Blood|July 2, 2008
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignanciesLuca Paoluzzi, Mithat Gonen, Govind Bhagat, et al.
Nucleic Acids Research|October 30, 2010
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemiaPrabodhika R Mallikaratchy, Alessandro Ruggiero, Jeffrey R Gardner, et al.
Blood|February 23, 2008
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphomaLuca Paoluzzi, Mithat Gonen, Jeffrey R Gardner, et al.
Hematological Oncology|June 4, 2026
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center StudyAndrew H Lipsky, Brian T Hill, Allison Winter, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Cancer Research|October 3, 2008
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugsMark L Heaney, Jeffrey R Gardner, Nicos Karasavvas, et al.
Cancer|July 29, 2009
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropeniaMark L Heaney, Edmond L Toy, Francis Vekeman, et al.
Nucleic Acid Therapeutics|July 16, 2013
A self-assembling short oligonucleotide duplex suitable for pretargetingPrabodhika Mallikaratchy, Jeffery Gardner, Lars Ulrik R Nordstrøm, et al.
Cancer|February 6, 2003
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericinTimothy B Aliff, Peter G Maslak, Joseph G Jurcic, et al.
Blood|July 2, 2008
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignanciesLuca Paoluzzi, Mithat Gonen, Govind Bhagat, et al.
Nucleic Acids Research|October 30, 2010
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemiaPrabodhika R Mallikaratchy, Alessandro Ruggiero, Jeffrey R Gardner, et al.
Blood|February 23, 2008
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphomaLuca Paoluzzi, Mithat Gonen, Jeffrey R Gardner, et al.
Hematological Oncology|June 4, 2026
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center StudyAndrew H Lipsky, Brian T Hill, Allison Winter, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Pageof 5